Y-mAbs to Participate in Upcoming Investor Conferences in September
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences. Michael Rossi, President and CEO, will represent the company at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:50 p.m. ET in New York, NY.
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET in New York, NY.
Both events will feature fireside chats and investor 1x1 meetings. Live webcasts of the fireside chats and related materials will be available on Y-mAbs' investor relations website under the Presentations section, with archives accessible for at least 30 days.
Y-mAbs Therapeutics (Nasdaq: YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in radioimmunoterapia innovativa e prodotti terapeutici a base di anticorpi per il trattamento del cancro, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Michael Rossi, Presidente e CEO, rappresenterà l'azienda ai seguenti eventi:
1. 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley il 6 settembre 2024, alle 13:50 ET a New York, NY.
2. Conferenza Globale sulla Salute di Cantor il 17 settembre 2024, alle 15:40 ET a New York, NY.
Entrambi gli eventi presenteranno chiacchierate informali e incontri 1x1 con gli investitori. Webcast dal vivo delle chiacchierate informali e materiali correlati saranno disponibili sul sito web delle relazioni con gli investitori di Y-mAbs nella sezione Presentazioni, con archivi accessibili per almeno 30 giorni.
Y-mAbs Therapeutics (Nasdaq: YMAB), una empresa biofarmacéutica en fase comercial especializada en nueva radioinmunoterapia y productos terapéuticos basados en anticuerpos para el tratamiento del cáncer, ha anunciado su participación en dos próximas conferencias de inversores. Michael Rossi, Presidente y CEO, representará a la empresa en:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley el 6 de septiembre de 2024, a la 1:50 p.m. ET en Nueva York, NY.
2. Conferencia Global de Salud de Cantor el 17 de septiembre de 2024, a las 3:40 p.m. ET en Nueva York, NY.
Ambos eventos incluirán charlas informales y reuniones 1x1 con inversores. Webcasts en vivo de las charlas informales y materiales relacionados estarán disponibles en el sitio web de relaciones con inversores de Y-mAbs en la sección de Presentaciones, con archivos accesibles durante al menos 30 días.
Y-mAbs 치료제(Nasdaq: YMAB)는 암 치료를 위한 새로운 방사면역 요법 및 항체 기반 치료 제품을 전문으로 하는 상장 단계의 생명공학 회사로, 다가오는 두 개의 투자자 회의에 참여할 예정이라고 발표했습니다. 마이클 로시 CEO가 다음 행사에서 회사를 대표할 것입니다:
1. 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스가 2024년 9월 6일 오후 1:50 ET에 뉴욕에서 열립니다.
2. 칸토 글로벌 헬스케어 컨퍼런스가 2024년 9월 17일 오후 3:40 ET에 뉴욕에서 열립니다.
두 행사 모두 비공식 대화 및 투자자 1대1 미팅이 포함됩니다. 실시간 웹 방송과 관련 자료는 Y-mAbs의 투자자 관계 웹사이트의 발표 섹션에서 제공되며, 아카이브는 최소 30일 동안 접근할 수 있습니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale spécialisée dans la radio-immunothérapie novatrice et les produits thérapeutiques à base d'anticorps pour le traitement du cancer, a annoncé sa participation à deux prochaines conférences pour investisseurs. Michael Rossi, Président et CEO, représentera l'entreprise lors des événements suivants :
1. 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 6 septembre 2024, à 13h50 ET à New York, NY.
2. Conférence Mondiale sur la Santé de Cantor le 17 septembre 2024, à 15h40 ET à New York, NY.
Les deux événements comprendront des discussions informelles et des réunions 1x1 avec les investisseurs. Des webcasts en direct des discussions informelles et des documents associés seront disponibles sur le site web des relations avec les investisseurs de Y-mAbs sous la section Présentations, avec des archives accessibles pendant au moins 30 jours.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der Kommerzialisierungsphase, das sich auf neuartige Radioimmuntherapie und antikörperbasierte therapeutische Produkte zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Michael Rossi, Präsident und CEO, wird das Unternehmen vertreten bei:
1. 22. jährliche globale Gesundheitskonferenz von Morgan Stanley am 6. September 2024 um 13:50 UHR ET in New York, NY.
2. Globale Gesundheitskonferenz von Cantor am 17. September 2024 um 15:40 UHR ET in New York, NY.
Beide Veranstaltungen werden informelle Gespräche und 1x1 Treffen mit Investoren beinhalten. Live-Webcasts der informellen Gespräche und zugehörige Materialien werden auf der Website der Investorenbeziehungen von Y-mAbs im Bereich Präsentationen verfügbar sein, wobei Archive mindestens 30 Tage lang zugänglich sind.
- None.
- None.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences:
| Morgan Stanley 22nd Annual Global Healthcare Conference Date: Friday, September 6, 2024 Time: 1:50 p.m. ET Location: New York, NY Format: Fireside chat and investor 1x1 meetings | |
| Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 3:40 p.m. ET Location: New York, NY Format: Fireside chat and investor 1x1 meetings | |
Live webcasts of Y-mAbs’ fireside chats and any accompanying materials will be available under the Presentations section of the Company’s investor relations website at ir.ymabs.com. The webcasts will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; All statements are subject to the risks described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When and where will Y-mAbs (YMAB) present at the Morgan Stanley Global Healthcare Conference in 2024?
What is the format of Y-mAbs' (YMAB) participation in the Cantor Global Healthcare Conference 2024?
Who will represent Y-mAbs (YMAB) at the upcoming investor conferences in September 2024?
How can investors access Y-mAbs' (YMAB) presentations from the September 2024 conferences?
